Immunization, Vaccines and Biologicals

Meeting of Strategic Advisory Group of Experts on Immunization (SAGE)

CCV, Geneva, 1 to 3 April 2014

Declaration of interests

All 14 SAGE members participating in the meeting updated their declaration of interest ahead of the meeting. Other meeting participants do not take part in the decision-making and are thus not required to complete a declaration of interest.

Eight members reported relevant interests, which were assessed not to constitute a conflict of interest. One member declared interests that could be perceived as a conflict specific to the pertussis session at the meeting. As a result Terence Nolan recused himself from participating in decision-making in relation with the agenda item on pertussis vaccines. It was concluded that all other members could take part in full in all of the discussions. All the reported relevant interests are summarized below:

Jon Abramson

  • His institution received a research grant in 2013 from MedImmune to conduct a post-marketing case-control study of the effectiveness of the quadrivalent live attenuated influenza vaccine. This interest was assessed as non-personal, specific and financially significant*.

Zulfiqar Bhutta

  • His department received in March 2011 a research grant from Novartis Global Health Institute on a Phase II trial of typhoid Vi conjugate vaccination. This interest was assessed as non-personal, non-specific and financially significant*.

Juhani Eskola

  • Received consultancy fees for membership in Novartis Data Safety Monitoring Board for typhoid vaccines. This interest was assessed as personal, non-specific and financially insignificant*.
  • Received consultancy fees for membership in Novartis Data Safety Monitoring Board for meningococcal vaccines. This interest was assessed as personal, non-specific and financially insignificant*.
  • His organization has a large joint research programme with GlaxoSmithKline on pneumococcal vaccines. This interest was assessed as non-personal, non-specific and financially significant*.

Peter Figueroa

  • His unit received a research grant in 2011 from Merck to conduct a small clinical trial of an anti-retroviral drug on HIV for which he was the principal investigator. All the funds from this research grant went into expenses to cover the cost of the trial and he received no payment for his contribution. This interest was assessed as non-personal, non-specific and financially significant*.

Terence Nolan

  • Received consultancy fees for participating in meetings and for data analysis and interpretation as member of Data and Safety Monitoring Board (DSMB) and Independent Data Monitoring Committee (IDMC) on Human Papilloma Virus vaccine from GSK.The consultancy was ceased by the 17th October 2012. This interest was assessed as personal, non-specific and financially significant*.
  • In the time from 2008-2012 his institution received research support for vaccine trials implemented in Australia from a number of companies (including GSK, Wyeth, Novartis Vaccines, sanofi pasteur and CSL Ltd).These trials concern a number of vaccines (MenACWY, MenB, MenC, HibMenC Adult and peadiatric TIV, H1N1 and H5N1 vaccine and DTPa-Hib-hepB-IPV-MenC vaccine). This interest was assessed as non-personal, specific and financially significant*.
  • His institution receives research support to conduct an influenza cell-based vaccine clinical trial from Novartis. This interest was assessed as non-personal, specific and financially significant*.
  • Received consultancy fees in 2011 from GSK for providing expert opinion to European jurisdiction in respect of clinical trial data from studies conducted by himself in the early 1990s sponsored by CSL ltd. This interest was assessed as personal, non-specific and financially insignificant*.
  • His institution receives research support to conduct a follow-up clinical trial on a birthdose of Pertussis Vaccination from GSK. This interest was assessed as non-personal, specific and financially significant*.
  • His institution receives research support to conduct a Meningococcal ACWY vaccine clinical trial from GSK. This interest was assessed as non-personal, non-specific and financially significant*.
  • Serves as principal investigator for a clinical trial assessing the antibody response and persistence following MenACWY-TT funded by GSK and Murdoch Childrens Research Institute. This interest was assessed as personal, non-specific and financially significant*.
  • Served on the Pertussis Scientific Advisory Board in March 2014. This interest was assessed as personal, specific and financially insignificant*

Kate O’Brien

  • Her institution provided consultancy to sanofi pasteur (2010 and 2011) and to Merck (currently) on pneumococcal vaccine. These interests were assessed as non-personal, non-specific and financially insignificant*.
  • Her institution provided consultancy to Pfizer (2011) and GSK (2011) on PCV. This interest was assessed as personal, non-specific and financially insignificant*.
  • Serves currently as member of DSMB on malaria RTSS vaccine funded by PATH-Malaria Vaccine Initiative. This interest was assessed as non-personal, non-specific and financially significant*.
  • Serves currently as member of DSMB on maternal influenza vaccine funded by Bill and Melinda Gates Foundation (BMGF). This interest was assessed as personal, specific and financially insignificant*.
  • Her institution received a research grant from Pfizer (completed 2012) regarding PCV13. This interest was assessed as non-personal, non-specific and financially significant*.
  • Her institution received a research grant from MedImmune (completed 2011) regarding RSV-motavizumab. This interest was assessed as non-personal, non-specific and financially significant*.
  • Her institution received a research grant from BMGF (completed 2012) regarding PCV serotype replacement. This interest was assessed as personal, non-specific and financially significant*.
  • Her institution currently receives research grants from GSK, BMGF, National Institutes on Health (NIH), and GAVI regarding pneumococcal and rotavirus vaccines. This interest was assessed as non-personal, non-specific and financially significant*.
  • Her institution currently receives research grants from BMGF regarding pneumonia etiology, technical country support and decision making in regard to pneumococcal and rotavirus disease, and vaccine demand support. This interest was assessed as non-personal, non-specific and financially significant*.

Claire-Anne Siegrist

  • Developed and owns the Viavac immunization management software destined to support Swiss health care professionals to follow the official immunization recommendations. Her ownership in the enterprise generates royalties of less than 5,000 USD per annum. This interest was assessed as personal, non-specific and financially insignificant*.
  • Her institution receives a research grant from sanofi pasteur on the immunology of novel adjuvants. This interest was perceived as non-personal, non-specific and financially significant*.

Piyanit Tharmaphornpilas

  • Received in 2011 a travel grant from a joint venture of the Thai Government Pharmaceutical Organization - Merieux Biological Product to attend the Re-invigorating Immunization Policy Implementation and Success: From Parent to Partner and from Broad to Engagement. This interest was assessed as personal, non-specific and financially significant*.

Fred Were

  • Served on advisory committee funded by GSK to assess severe side effects of malaria vaccine. This interest was assessed as personal, non-specific and financially insignificant*.
  • Serves on the GSK monitoring committee for the malaria vaccine challenge trial. This interest was assessed as non-personal, non-specific and financially insignificant*.
  • Serves on the PATH advisory board for the whole cell pneumococcal vaccine. This interest was assessed as non-personal, non-specific and financially insignificant*.
  • Facilitates educational workshops for health-care workers on immunization topics, in particular PCV & Rotavirus vaccine impact. This interest was assessed as personal, non-specific and financially insignificant*.

* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single vaccine manufacturer or other vaccine-related company exceeds 5,000 USD in a calendar year. Likewise, a shareholding in any one vaccine manufacturer or other vaccine-related company in excess of 1,000 USD would also constitute a “significant shareholding”.

Share